

## Utah Cannabis Research Review Board Meeting Minutes

Tuesday, February 14, 2023, 9:00am-11:00am

This meeting was held virtually and was recorded. An audio copy of this recording can be found on the Utah Public Notice Website (<https://www.utah.gov/pmn/>) and on the Cannabis Research Review Board YouTube channel at <https://www.youtube.com/channel/UCJW8IN0h7wQ3ojY33gZC8cw>

### **Attendees \*\*\*\*this needs to still be updated\*\*\*\***

Board members present: Katherine Carlson, Matt McIlff, Jennifer Norris, Mike Moss, Perry Fine, Misty Smith, Brian Zehnder

DHHS staff attending: Rich Oborn, Sarah Ponce, Sara Lealos, Jeremiah Sniffin, Jesse Hawkley, Lauren Heath, Daisha Montgomery

#### 1. Welcome – Dr. Carlson

At 9:02 AM the board chair Dr. Carlson, called the meeting to order.

#### 2. Approval of January 2023 minutes – Dr. Carlson

Dr. McIlff motioned to approve the minutes. Dr. Zehnder seconded. The minutes were approved unanimously.

#### 3. Dose guidelines – Dr. Fine

Dr. Fine presented the "Guideline for initiation and titration of oral cannabis products in adults" document and provided a brief history of what went into creating it. The document is a summary of a cannabis treatment guideline for education and guidance purposes. It is intended to be used by clinicians and patients. It is a work in progress and is subject to change as more research and science regarding medical use of cannabis becomes available.

Dr. McIlff made a motion to approve the guideline, Dr. Norris seconded. The guideline document was approved by the board unanimously.

#### 4. Product list/formulary – Dr. Carlson

Dr. Carlson stated that having dosing guidelines will not be helpful if the products available for purchase in the medical cannabis pharmacies do not align with recommended dosages.

Rich stated that a data analyst in the Center for Medical Cannabis (CMC) is pulling data from the inventory control system (ICS) database to categorize medical cannabis products available for purchase in the market broken down by various dosage types (concentrates, flower, gummies) and those that are low THC, medium THC, and high THC. There are some limitations in the data that have made this project challenging but Mr. Oborn expects to have information to share with the board during the next board meeting. The long-term plan is to work with a software vendor to help improve data parameters, identify specific descriptors, and specify rules pertaining to data that processors enter into the data.

Dr. Hofmann suggested that the CMC provide board members with a formal presentation on the CMC auditing process used to regulate medical cannabis pharmacies. Dr. Hofmann has asked the CMC to schedule that prior to the next board meeting in March 2023. Dr. Carlson agreed that a formal presentation would be helpful.

#### 5. Highway safety updates– Dr. Moss

Dr. Moss discussed the highway safety updates from the quarterly meeting that he attends. He shared information about driving impairment and how to detect and identify threshold levels and specific contents. It is challenging to attribute accidents directly to cannabis use. The data that is available does not go in depth for cannabis impairment. It would be helpful to have grant money to invest in projects to research driving impairment data more extensively.

Dr. Carlson stated that It is important to inform patients about how cannabis may impair their driving. Mr. Oborn informed the board that each product container has a label with the following warning: **WARNING: Cannabis has intoxicating effects and may be addictive. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a recommending medical provider.** There was discussion about the need to do more to inform patients about the intoxicating effects of cannabis use.

Dr. Moss will continue to attend the quarterly meetings.

#### 6. Insomnia Material and CUD speaker announcement – Dr. Carlson

Legislators asked the board to conduct a review and provide recommendations related to insomnia and cannabis use disorder (CUD).

Dr. Carlson asked the board to read through all content related to insomnia provided to them via email. She asked the board to provide feedback via email. Dr. Carlson asked Ms. Health to conduct research to

assist with the board's response to lawmakers.

Dr. Adam Gordon has been invited to present to the board about cannabis use disorder and the potential public risks attributed to the disorder.

7. DHHS updates – Rich Oborn, CMC Director Mr. Oborn provided the board with updates on legislation impacting medical cannabis during the 2023 legislative session. Mr. Oborn discussed the following bills.

- [HB 72 medical cannabis governance revisions](#)
- [HB 230 center for medical cannabis research](#)
- [SB 137 medical cannabis amendments](#)
- [SB 91 medical cannabis regulation amendments](#)
- [HB 227 hemp amendments](#)
- [HB 200 psilocybin prescription amendments](#)

8. Board comment - 10:30 AM (10 min.)

Dr. Moss asked if SB 91 requires that there be evidence of a medical cannabis product ingredient being poisonous or deleterious in order for a public health authority to recommend that it be banned or limited.

Mr. Oborn explained that the bill does not require that there be evidence that the ingredient to be banned or limited is poisonous.

9. Public comment - 10:40 AM (20 min.)

Dr. Mark Viner is a psychiatrist in Nevada. Dr. Viner commented on the dosing guidelines approved by the board and how we do not know how much or how long a person can take CBD and not be harmed. He also asked if the state of Utah tests products for plant viral infection. Mr. Oborn indicated that he would contact UDAF and find out.

Zac Newel King is a patient advocate/patient with TRUCE. Mr. King emphasized the importance of reducing synthetics in the market which have proven to cause harm. Mr. King commented that more research and quality testing should be done on synthetic cannabinoids prior to them being available for purchase. Patients should have a right to obtain a copy of their certificate of analysis.

Mr. Oborn commented that Utah law allows patients to obtain a copy of a certificate of analysis for a product.

## 10. Adjourn

Dr. Carlson asked the board for a motion to end the meeting. Dr. Zender motioned to adjourn Dr. Norris second the motion. Vote to adjourn was unanimous.

The meeting adjourned 10:47 AM

DRAFT